Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02290600 · ClinicalTrials.gov registry record
Feasibility Study Using Run-to-Run Control to Optimize Continuous Glucose Sensor Bias
A clinical trial, sponsored by Sansum Diabetes Research Institute.
- Completed
- Registry status
- 23
- Enrollment target
NCT02290600: Completed study, sponsored by Sansum Diabetes Research Institute.
NCT02290600 is a clinical trial that has completed, run by Sansum Diabetes Research Institute. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02290600 has completed, sponsored by Sansum Diabetes Research Institute.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The purpose of this 12 week feasibility study is to see how much more accurate a continuous glucose monitor (CGM) might be in individuals with type 1 diabetes if the investigators personalize sensor calibrations to the user, based on previous wear.
Interventions
- DEVICE Continuous Glucose Monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-12 |
What the finished NCT02290600 record still lists
NCT02290600 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Continuous Glucose Monitor is the first listed.
NCT02290600 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02290600 about?
NCT02290600 is a clinical study titled "Feasibility Study Using Run-to-Run Control to Optimize Continuous Glucose Sensor Bias". The purpose of this 12 week feasibility study is to see how much more accurate a continuous glucose monitor (CGM) might be in individuals with type 1 diabetes if the investigators personalize sensor calibrations to the user, based on previous wear.
What is the current status of trial NCT02290600?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2015-01. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02290600?
The interventions under investigation include: Continuous Glucose Monitor (DEVICE).
Who is sponsoring clinical trial NCT02290600?
This trial is sponsored by Sansum Diabetes Research Institute, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia